Dermatitis News and Research

Latest Dermatitis News and Research

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

ZymoGenetics, Inc. announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.

21 May 2010

Ectoin shows positive effect on nanoparticle-induced lung inflammation: Study

bitop AG, which specializes in the development and marketing of Ectoin-containing medical devices, announces that Ectoin significantly reduces nanoparticle-induced inflammatory reaction in rat lungs, one of the animal models for chronic obstructive pulmonary disease. It is the first time that Ectoin has been shown to have such an effect on nanoparticle-induced lung inflammation.

20 May 2010

Expert 'top tips' for management of childhood eczema

Several leading European dermatologists have launched guidance to help parents reduce the burden of eczema on children living with this disease. Experts from Denmark, France, Germany, Poland and Spain have come together to agree a consensus of 'top tips', which focus on avoiding situations that trigger painful flares and different ways to increase eczema 'flare-free' periods. The 'top tips', sponsored by Astellas Pharma Europe Ltd., are launched at the 10th European Society for Pediatric Dermatology Congress (ESPD), Switzerland.

20 May 2010

Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010

14 May 2010

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week (DDW) meeting held in New Orleans, Louisiana.

5 May 2010

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it received a complaint filed by Celgene Corporation seeking a declaration from the court that four Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene's products and are invalid.

3 May 2010

VIMOVO delayed-release tablets receive FDA approval

AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

3 May 2010

Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.

29 Apr 2010

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.

27 Apr 2010

Nuvo Research's PENNSAID now available in U.S. pharmacies

Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that PENNSAID(R) (diclofenac sodium topical solution) 1.5% w/w, is now available by prescription in U.S. pharmacies.

27 Apr 2010

Covidien introduces PENNSAID to the U.S. market

Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

26 Apr 2010

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010.

22 Apr 2010

DiscoveryBioMed awarded NIH SBIR Phase 1 grant to discover and develop anti-inflammatory phytochemicals

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $200,000 Small Business Innovations Research (SBIR) Phase 1 grant by the National Institutes of Health (NIH) to continue research into the discovery and development of anti-inflammatory phytochemicals to address complications associated with nasal and pulmonary inflammation, dermatitis, and kidney disorders with an inflammatory component.

21 Apr 2010

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

YM BioSciences Inc., announced the pre-publication of pivotal preclinical data for CYT387, the company's highly selective and potent JAK1/2 inhibitor, currently in a Phase I/II trial for myelofibrosis.

19 Apr 2010

Investment group acquires Arbor Pharmaceuticals

Arbor Pharmaceuticals, a specialty pharmaceutical company focused on pediatric medicine, announced today that an investment group led by Jason Wild of JW Asset Management, LLC and Edward Schutter has acquired the company.

15 Apr 2010

Asthma-like symptoms in infants and toddlers is often RAD

Your child is wheezing. Your child must have asthma, right? Not always, says Julie Koehler, professor and chair of the Department of Pharmacy Practice in Butler University's College of Pharmacy and Health Sciences and clinical pharmacy specialist in family medicine at Clarian Health.

12 Apr 2010

Mayo Clinic Health Letter: UV light slows skin cell overgrowth, alters immune system

Ultraviolet light -- a culprit behind sunburns, wrinkles and skin cancer -- offers benefits for some skin conditions, according to the April issue of Mayo Clinic Health Letter.

9 Apr 2010

U.S. Marshals seizes unapproved drug products

At the request of the U.S. Food and Drug Administration, U.S. Marshals on March 31 seized a range of consumer products, including creams, capsules, tablets, gum, throat spray, and shampoos from a Haywood, Wis., manufacturer.

6 Apr 2010

Dermatitis News and Research

Latest Dermatitis News and Research

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Genentech to present new data for targeted cancer medicines at 46th ASCO

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

Ectoin shows positive effect on nanoparticle-induced lung inflammation: Study

Expert 'top tips' for management of childhood eczema

Cyclacel Pharmaceuticals reports net loss of $5.1M for first-quarter 2010

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

VIMOVO delayed-release tablets receive FDA approval

Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Nuvo Research's PENNSAID now available in U.S. pharmacies

Covidien introduces PENNSAID to the U.S. market

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

DiscoveryBioMed awarded NIH SBIR Phase 1 grant to discover and develop anti-inflammatory phytochemicals

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

Investment group acquires Arbor Pharmaceuticals

Asthma-like symptoms in infants and toddlers is often RAD

Mayo Clinic Health Letter: UV light slows skin cell overgrowth, alters immune system

U.S. Marshals seizes unapproved drug products

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Dermatitis News and Research

Latest Dermatitis News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in